Randomized phase II study of dexamethason for anorexia in patients with advanced lung cancer

Randomized phase II study of dexamethason for anorexia in patients with advanced lung cancer - Randomized phase II of dexamethason for anorexia in lung cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022448

Enrollment

Registered

2016-07-01

Start date

2016-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced lung cancer

Interventions

Dexamethason 1mg Dexamethason 4mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Advanced lung cancer with grade3 (NCI-CTC) anorexia 2. Performance status 2-3 3. 20 years old or older 4. No chemotherapy within 2 weeks (>12 weeks responder with EGFR- or ALK-TKI were eligible) 5. Addequate organ function 6. >2 months life expectancy 7. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Contraindication for steroid use 2. Already use of steroid for other disease 3. Uncontrolled co-morbidities such as heart failure or renal failure 4. Symptomatic brain metastasis 5. Uncontrolled cancer pain 6. Other drugs for anorexia within 2 weeks 7. Acute exacerbation of lung cancer 8. Suspicios of bowel obstruction 9. Unable to answer questiones regarding appetite and QOL 10. Other inappropriate conditions for clinical trial

Design outcomes

Primary

Measure	Time frame
NRS of anorexia at day 7	—

Countries

Japan

Contacts

Public ContactAkira Inoue

Tohoku University School of Medicine Department of Palliative Medicine

akira.inoue.b2@tohoku.ac.jp022-717-7366

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026